The General Hospital Corporation

Dana-farber-cancer Institute Inc.

J.m. Huber Corporation

Kemira Oyj

Other

Chevron U.s.a. Inc.

Raytheon Company

Thomas J Lynch

Pasi Antero Janne

Daniel Arie Haber

Matthew Meyerson

William R Sellers

Raffaella Sordella

Jeffrey E Settleman

Daphne Winifred Bell

Juan Guillermo Paez

Gary M Freeman

Bruce E Johnson

Carl J Marshall, Jr

Bruce E Johnston

Dennis Arun Alexis

Do Hoon Kim

Hong Yang

Sukhjit Aujla

Logan Jackson

Frances Fournier

Ronald Robinson

Aleksey Isarov

Walter O Lackey

David A Cuddeback

Varadarajan Dwarakanath

Taimur Malik

Scott Rosencrance

Yuping Luo

Jiang Li

David R Espinosa

Jenna Rabideau

Larry R Evans

Christina D Prowell

Dwayne E Outlaw

Marc Finkelstein

Martin J Geesaman

Jenna Sue Rabideau

A phytochemical and nutraceutical composition and method for protection against a wide spectrum of viral and bacterial infections, including Covid-19, and for treatment of established infection and infectious inflammation. The composition includes a novel combination of vitamin, mineral, nutraceutical and phytochemical supplements. The composition of supplements and method may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals and phytochemicals provided, respectively, as immune boosters and antiviral agents along with anti-inflammatory nutraceuticals and phytochemicals.

Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

An inverse emulsion composition comprising: one or more hydrophobic liquids having a boiling point at least about 100&#xb0; C.; up to about 38% by weight of one or more acrylamide-(co)polymers; one or more emulsifier surfactants; and one or more inverting surfactants; wherein, when the composition is inverted in an aqueous solution, it provides an inverted solution having a filter ratio using a 1.2 micron filter (FR1.2) of about 1.5 or less.

Inverse emulsion compositions

Provided herein are liquid polymer (LP) compositions comprising an acrylamide (co)polymer, as well as methods for preparing inverted polymer solutions by inverting these LP compositions in an aqueous fluid. The resulting inverted polymer solutions can have a concentration of acrylamide (co)polymer of from about 50 to about 15,000 ppm, and a filter ratio of 1.5 or less at 15 psi using a 1.2 &#x3bc;m filter. Also provided are methods of using these inverted polymer solutions in dewatering, clarification, flocculation and/or thickening applications, and the like.

Polymer compositions and methods of use

The present disclosure relates to a method and composition for increasing wet and/or dry strength of a paper product. The method comprises adding a composition comprising at least one polymer having a molecular weight more than 0.5 million Dalton and a degradation agent to a pulp suspension, and forming said paper product.

Composition for use as a paper strength agent

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

A mineral slurry comprises mineral particles in an amount equal to or greater than about 60 percent by total weight of the slurry, wherein 85 percent of the mineral particles have an average particle size equal to or less than 2 micrometers; a polyelectrolyte dispersant derived from an acrylate polymer formed by reversible addition-fragmentation chain transfer polymerization, wherein the polyelectrolyte dispersant comprises endgroups comprising thio-containing residues derived from a trithiocarbonate chain transfer agent, wherein the polyelectrolyte dispersant is in an amount less than about 35 pounds of the dispersant per ton of dry mineral particles, and wherein the polyelectrolyte dispersant has a molecular weight of 3000 to 10,000 Daltons and a polydispersity of at least 1.0 and less than 1.5; and the remainder water.

Mineral dispersants and methods for preparing mineral slurries using the same

Disclosed is a silica substrate treated with a polysiloxane, and an organosilane, wherein the organosilane is described by the formula: RSi(R')(OR&#x2033;); wherein R is a long-chain hydrocarbon group having between about 8 to about 30 carbon atoms, which may also contain organofunctional groups such as vinyl, methacryl, amino, sulfur, and epoxy groups; R&#x2032; and R&#x2033; are independently selected from a methyl and ethyl group; and X is either 0 or 1. The optimal use for the treated silica substrate is as a rheology modifier in epoxy polymer materials, however, the silica substrate could also be used in other chemical compositions such as polyurethanes, polyesters, silicones, and hydrocarbon oils.

Surface treated silicas

Growing community of inventors

Roswell, GA, United States of America

Thomas J Lynch